Bionano Genomics announces publication of a breast cancer study with OGM

Bionano Genomics announced the publication of a study of optical genome mapping, OGM, in hereditary breast and ovarian cancer, HBOC, syndrome showing that when tumors exhibited higher overall numbers of structural variations they tended to have more mutated genes and altered signaling pathways, which may correlate with poor prognosis, tumor progression and chemotherapy resistance. Researchers also found that OGM was able to detect chromothripsis events and novel gene fusions in cancer tissues with high accuracy, including novel gene fusions that were not detected by other methods. “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential. We believe the comprehensive assessment of the role SVs play in breast cancers with abnormal DNA repair functions might expand our current understanding of disease progression and precision medicine in breast cancer,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.